


IN THE CLAIMS

Please amend the claims as follows:

Claims 1-5 (Cancelled).

Claim 6 (New): A method of treating neutrophilia in a mammalian subject in need of such treatment, the method comprising administering a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to the subject to treat neutrophilia:




wherein each of R¹, R² and R³ is independently a hydrogen atom or a C₁₋₆ alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C₁₋₈ alkylene or a C₁₋₈ alkylene substituted with a hydroxyl group.

Claim 7 (New): The method according to Claim 6, wherein in the formula (I), R¹ and R² are hydrogen atoms, R³ is a hydrogen atom or a C₁₋₄ alkyl group, X is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a C₁₋₅ alkylene or a C₁₋₈ alkylene substituted with a hydroxyl group.

Claim 8 (New): The method according to Claim 6, wherein the compound represented by the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.

Claim 9 (New): The method according to Claim 6, wherein the pharmaceutically acceptable salt is an organic acid salt or an inorganic acid salt.

Claim 10 (Currently Amended): A method for treating chronic obstructive pulmonary disease in a mammalian subject in need of such treatment, the method comprising administering a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmaceutically acceptable salt thereof to the subject to treat chronic obstructive pulmonary disease:



wherein each of R¹, R² and R³ is independently a hydrogen atom or a C₁₋₆ alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C₁₋₈ alkylene or a C₁₋₈ alkylene substituted with a hydroxyl group.

Claim 11 (New): The method according to Claim 10, wherein in the formula (I), R¹ and R² are hydrogen atoms, R³ is a hydrogen atom or a C₁₋₄ alkyl group, X is a halogen atom, Y is a halogen atom or a hydrogen atom, and A is a C₁₋₅ alkylene or a C₁₋₈ alkylene substituted with a hydroxyl group.

Claim 12 (New): The method according to Claim 10, wherein the compound represented by the formula (I) is 4-bromo-6-[3-(4-chlorophenyl)propoxy-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone.

Claim 13 (New): The method according to Claim 10, wherein the pharmaceutically acceptable salt is an organic acid salt or an inorganic acid salt.